As of February 2026, CAR-T therapy is not used as a first-line treatment. Patients may become eligible after one to three prior lines of therapy, depending on multiple clinical factors.
CAR-T therapy is currently approved primarily for specific blood cancer indications and for certain autoimmune and rheumatologic diseases.
To determine whether your condition may be suitable for CAR-T therapy, please provide the following:
- A copy of the patient’s passport
- A medical summary from the treating physician or oncologist, including the date of initial diagnosis and details of prior treatments and medications (in English or translated into English).
Once we receive the documents, the application will be reviewed by a specialist in the relevant field, who will assess whether CAR-T therapy may be appropriate in your case. If suitable, we will provide an initial treatment outline and estimated cost.
The final decision regarding CAR-T therapy is made by the patient in consultation with their treating physician.
This evaluation service is provided at no charge.
Please send your documents via your preferred method:
Telephone: +972-54-575-0331
WhatsApp: +972-54-575-0331
Email: contact@mashmed.com
